Zeitschrift für molekulare Biomarker und Diagnose

Analysis on the Potential Clinical Bio-marks for Decabromodiphenyl Ether Exposure

Abstract

Hongmei Wang, Beidou Xi, Hongyan Wang, Han Zhang, Congli Ma, Yuguo Jiao and Yuejiao Zhang

Decabromodiphenyl ether (BDE 209) was one of the flame retardants in a variety of commercial and household products. The toxicity of BDE 209 was thought to be associated with neurotoxicity, changes in fetal development, and endocrine disruption etc. Although different toxicology effects of BDE 209 exposure had been reported, the information of BDE 209 on Jurkat cells was still insufficient, and the molecular bio-marks were still unknown. In this research, the gene expression profiling was analyzed. Changes of gene expression induced by BDE 209 could be classified into neurotoxicity, apoptosis and reproductive toxicity. Quantifying microRNA expression levels was verified by real-time PCR. The expression levels of Brain-Derived Neurotrophic Factor (BDNF), Regulating synaptic membrane exocytosis 3 (RIMS3) and dihydropyrimidinase-like 3 (DPYSL3), which were associated with the neurotoxicity and brain development, presented trends of down-regulated. Based on the abundance of gene expression analysis in tissues and cells and taking the possibility of biological samples obtained for the clinical diagnosis into consideration, BDNF, that had been confirmed as one of the key genes in the neurotoxicity, was recommended as one of the main clinical bio-marks in the epidemiology, since it had been found abundant in the blood monocyte.